Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Volitionrx (VNRX) over the last 7 years, with Q3 2025 value amounting to $80381.0.

  • Volitionrx's Gains from Investment Securities rose 40681.59% to $80381.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $242661.0, marking a year-over-year increase of 3423.45%. This contributed to the annual value of $139939.0 for FY2024, which is 3136.14% down from last year.
  • Latest data reveals that Volitionrx reported Gains from Investment Securities of $80381.0 as of Q3 2025, which was up 40681.59% from $55057.0 recorded in Q2 2025.
  • In the past 5 years, Volitionrx's Gains from Investment Securities ranged from a high of $123647.0 in Q4 2023 and a low of $102.0 during Q4 2021
  • Its 5-year average for Gains from Investment Securities is $45616.0, with a median of $38205.0 in 2024.
  • As far as peak fluctuations go, Volitionrx's Gains from Investment Securities soared by 2950392.16% in 2022, and later crashed by 7864.12% in 2024.
  • Volitionrx's Gains from Investment Securities (Quarter) stood at $102.0 in 2021, then soared by 29503.92% to $30196.0 in 2022, then soared by 309.48% to $123647.0 in 2023, then crashed by 33.03% to $82812.0 in 2024, then decreased by 2.94% to $80381.0 in 2025.
  • Its last three reported values are $80381.0 in Q3 2025, $55057.0 for Q2 2025, and $24411.0 during Q1 2025.